3627 results for «686»

Filter By

3627 results

Redefining precision and performance in TAVI: advancing clinical outcomes with the Evolut FX+ system

10 Oct 2025 – From AICT-AsiaPCR 2025

Delve into advanced transcatheter aortic valve implantation (TAVI) with the Evolut FX plus system, focusing on its application in patients with small annulus and coronary artery disease (CAD). This session details step-by-step deployment, patient selection, imaging analysis, and highlights the distinctions from the previous Evolut R...

Complex femoral access for TAVI in bicuspid aortic stenosis - LIVE Case

30 Sep 2025 – From PCR Gulf Valves 2025

74 year-old male with history of multiple PCI, PAD, Type 2 DM, presented a symptomatic bicuspid aortic stenosis with a preserved LV function.

They implant a myval 26 mm by right femoral artery access with a right radial secondary access, after a predilation (Balloon 20mm). They prepare...

Complex femoral access for TAVI in bicuspid aortic stenosis - LIVE Case

Step-by-step TAVI for mixed bicuspid aortic valve disease - LIVE Case

30 Sep 2025 – From PCR Gulf Valves 2025

A 65-year-old female with a history of diabetes and moderate left ventricular dysfunction (LVEF 50%) presented with symptomatic severe bicuspid aortic stenosis associated with moderate-to-severe aortic regurgitation. A 26 mm Sapien Resilia valve was implanted under local anesthesia via femoral artery access, with right radial secondary...

Step-by-step TAVI for mixed bicuspid aortic valve disease - LIVE Case

2 year follow-up of the MITRA-FR study: effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation

03 Sep 2019

At the ESC Congress 2019 in Paris, Jean-François Obadia presented the results of the 2 years follow-Up of the MITRA-FR study. Read the report by Nicole Karam.

2 year follow-up of the MITRA-FR study: effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation

A randomised trial comparing imaging-guided PCI with Orsiro vs Xience

18 May 2021

Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...

Authors :

A randomised trial comparing imaging-guided PCI with Orsiro vs Xience

RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

05 Sep 2023

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Alessandro Sticchi

Author

Alessandro Sticchi
RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

BIOFLOW DAPT - Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk: A randomized, open-label clinical trial

26 Aug 2023

Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.

BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...

Nicola Ryan

Author

Nicola Ryan
BIOFLOW DAPT - Biodegradable polymer SES vs durable polymer ZES in HBR subjects with 1-month DAPT
Didn’t find what you were looking for?